**Supplementary table 1: Clinical characteristics during initial attack and follow-up.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Patient. Sex,age | ApoE genotype | Clinical presentation | Treatment | | Relapse / hemorraghe  delay (months) | mrs at discharge | Mrs end of Follow-up | Follow-up (months) |
| Steroids  (duration, months), | Immunosuppressive (duration, months) |
| 1. M 68 | 3/3 | Aphasia | P\* (22) | No | R (4) | 1 | 1 | 21 |
| 2. F 82 | NA | Decrease consciousness | MP, P (1) | No | H (1) | 3 | death | 1 |
| 3. F 77 | 3/4 | Confusion, hemiparesis | MP, P (6) | No | No | 1 | 1 | 28 |
| 4. M 71 | 4/4 | Confusion, aphasia | MP, P (12) | No | No | 2 | 1 | 41 |
| 5. F 67 | 3/3 | Confusion, aphasia | MP, P (4) | No | No | 3 | death | 6 |
| 6. M 67 | 4/4 | Confusion, hemiparesis, VS | MP, P (3) | No | R (2) | 0 | death | 20# |
| 7. M 69 | 3/4 | Confusion, hemiparesis | MP, P (13) | AZT\* (5) | R (8) | 1 | 0 | 13 |
| 8. M 63 | 4/4 | Epilepsy | MP, P (17) | MM, CP\* (8) | R (8) | 1 | 1 | 17 |
| 9. F 76 | 4/4 | Confusion | P (3) | No | No | 0 | 0 | 12 |
| 10. F 76 | NA | Hemiparesis | P (2) | No | No | 1 | 1 | 8 |
| 11. M 84 | 3/4 | Headache, VS | P (13) | MM (13) | No | 2 | 2 | 13 |
| 12. F 71 | 3/3 | Confusion, hemiparesis | MP\*, P\* (1) | No | R (9) | 3 | 3 | 10 |
| 13. M 55 | 4/4 | Headache | MP, P (31) | CP, AZT\* (57) | R (3) | 0 | 1 | 67 |
| 14. F 70 | 2/3 | Epilepsy | MP, P (10) | AZT (10) | R (7) | 2 | death | 11 |
| 15. F 81 | 4/4 | Confusion, hemiparesis | MP, P (9) | MM (9) | No | 2 | 3 | 9 |
| 16. F 64 | 4/4 | Confusion, aphasia | P\*(17) | CP, MM\*(28) | R (22) | 0 | 4 | 46 |
| 17. M 65 | 4/4 | Headache, VS | No | No | R (9) | 0 | 1 | 11 |
| 18. F 81 | 4/4 | Confusion, aphasia, hemiparesis | P\* (5) | CP\* (1) | R (4) | 0 | death | 13 |
| 19. M 73 | 3/4 | Hemiparesis | No | MM (12) | No | 0 | 0 | 25 |
| 20. F 71 | NA | Hemiparesis | P (22) | No | R (11) | 1 | 3 | 62 |
| 21. F 76 | NA | Confusion, aphasia | MP, P (3) | No | No | 2 | 4 | 92 |
| 22. M 66 | 4/4 | Epilepsy | No | No | No | 0 | 2 | 60 |
| 23. F 79 | NA | Confusion, headache | MP, P (1) | No | No | 1 | 1 | 22 |
| 24. M 69 | NA | Confusion, VS | P (2) | No | H (1) | 3 | death | 4 |
| 25. M 79 | 2/3 | Confusion, aphasia | No | No | No | 2 | death | 11 |
| 26. F 71 | 3/3 | Confusion, aphasia, VS | MP, P (6) | CP (6) | H (1) | 3 | 4 | 36 |
| 27. F 81 | NA | Hemiparesis | P (6) | No | H (36) | 0 | death | 36 |
| 28. M 66 | NA | Confusion, VS | P (36) | LND (18) | R(55),H(58) | 0 | 3 | 91 |

VS: visual symptoms

R: relapse

H: hemorrhage

MP: intravenous methylprednisolone

P: prednisone/prednisolone

AZT: aziathioprine

MM: mycophenolate mofetil

CP: cyclophosphamide

LND: lenalidomide (multiple myeloma immunosuppressant therapy)

\* Treatments given only after the first relapse

# unrelated cause of death (cancer)